Dare Bioscience, Inc. — FY2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020; comparison is with FY2019. Dare is a clinical-stage biopharmaceutical company focused on women’s health. It has no approved or commercialized products and generated no product revenue.
Financial performance and position
| Metric | FY2020 / Dec. 31, 2020 | FY2019 / Dec. 31, 2019 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $20.8 million | $8.5 million |
| General and administrative expense | $6.5 million | $5.3 million |
| Total operating expenses | $27.4 million | $14.3 million |
| Net loss | $27.4 million | $14.3 million |
| Net loss per share, basic and diluted | $0.91 | $0.97 |
| Net cash used in operating activities | $25.2 million | $13.3 million |
| Cash and cash equivalents | $4.7 million | $4.8 million |
| Working capital | Deficit of $0.7 million | Not stated in the cited discussion |
| Total liabilities | $8.7 million | $7.0 million |
| Stockholders’ equity (deficit) | Deficit of $1.2 million | $0.4 million equity |
No gross margin is reported because the company had no revenue. Operating cash outflow increased year over year. Financing activities provided $25.1 million in FY2020, largely through common-stock sales and warrant exercises; the resulting cash balance was slightly lower than at year-end 2019. The company reported no off-balance-sheet arrangements.
Material changes and notable developments
- R&D expense rose 143%, primarily due to the DARE-BVFREE Phase 3 trial and Ovaprene manufacturing and regulatory work. Grant funding was recorded as a reduction to R&D expense.
- Net loss increased 92%. The FY2020 loss per share was lower than in 2019 despite the larger net loss, reflecting a higher weighted-average share count.
- Common shares outstanding increased from 19.7 million to 41.6 million during 2020. The company raised approximately $23.5 million gross from equity sales during 2020 and, through March 29, 2021, reported approximately $11.3 million of further net proceeds from ATM and equity-line sales.
- DARE-BV1’s Phase 3 DARE-BVFREE trial met its primary and prespecified secondary endpoints. The primary endpoint cure rate at Day 21–30 was 70.2% for DARE-BV1 versus 35.6% for placebo in the modified intent-to-treat population (p<0.001). Treatment-related adverse events were reported in 15.3% versus 9.7%; vulvovaginal candidiasis was more frequent with DARE-BV1.
- Ovaprene’s postcoital pilot study met its sperm-motility endpoint, but this does not establish contraceptive effectiveness. A pivotal study and FDA review remain outstanding.
- The Phase 1 DARE-HRT1 study completed enrollment in March 2021; topline results were anticipated in Q2 2021. The Sildenafil Cream 3.6% Phase 2b trial began in March 2021, with topline results targeted by year-end 2021.
Outlook, risks and unusual items
- Going concern: The auditor and management state that recurring losses, negative operating cash flow, and dependence on additional financing raise substantial doubt about the company’s ability to continue as a going concern. Management estimated available cash was insufficient for working-capital needs and other liquidity requirements for the 12 months following issuance of the financial statements. Additional capital is necessary; availability and terms are uncertain.
- Expected spending: Management expected 2021 R&D expense could be more than double FY2020 if programs advanced as planned. The planned Sildenafil Cream Phase 2b trial was estimated to cost $15–$17 million, not all payable in 2021. Management also cited up to $4.5 million of potential license milestones and approximately $1.0 million of Microchips contingent consideration in 2021.
- DARE-BV1: The company planned to submit an NDA by the end of Q2 2021 and request priority review. Early-2022 U.S. launch was conditional on timely filing, priority review, and FDA approval in 2021; none was assured. The company also anticipated a PDUFA user-fee waiver, subject to FDA approval.
- Ovaprene/Bayer: Bayer paid a $1.0 million upfront fee, recorded as deferred revenue at year-end. Bayer may choose, in its sole discretion, to pay a further $20.0 million after reviewing pivotal-trial results, activating its U.S. commercialization license. Bayer may terminate on 90 days’ notice. Future milestone and royalty proceeds depend on development and commercial success.
- COVID-19 and execution: The company warned that the pandemic could delay or raise the cost of trials, regulatory work, supply, and fundraising. It relies on third parties, including single-source suppliers, and has no internal sales or marketing infrastructure.
- Other items: A $367,000 PPP loan was recorded as a liability at December 31, 2020; the SBA forgave principal and interest in January 2021. A $1.0 million current contingent-consideration liability related to the Microchips acquisition was expected to become payable in the first half of 2021. Management reported effective disclosure controls and internal control over financial reporting; no auditor attestation of internal controls was required. No material legal proceedings were reported.
Important facts for investors to verify
- Current cash runway, financing completed after March 29, 2021, and the company’s ability to fund its planned clinical and regulatory programs.
- Final DARE-BVFREE results, NDA filing and FDA acceptance, any request for additional studies, and the actual review designation and decision timeline.
- Ovaprene pivotal-trial design, IDE status, enrollment and results, and whether Bayer elects to pay the $20.0 million fee or terminates the agreement.
- 2021 trial progress and data for Sildenafil Cream and DARE-HRT1, including costs, enrollment, safety, and any timeline changes.
- Further share issuance, outstanding options and warrants, and dilution; the filing reports 47,312,822 common shares outstanding as of March 29, 2021.
- Supplier capacity, commercial manufacturing arrangements, grant funding conditions, and the timing and form of contingent milestone payments.